Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

• Market Cap: $2.02B
• Dividend Yield: N/A
• Average Volume (3M): 894.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 59.45%
• EPS Growth: -290.38%
• Country: US
• Employees: 315
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 42,336,227
• 10 Day Avg. Volume: 544,555
• 30 Day Avg. Volume: 894,938
• PEG Ratio: -1.94
• Price to Book (P/B): 4.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 46.67
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 1.17
• Enterprise Value/Gross Profit: 4.88
• Enterprise Value/Ebitda: -17.27
• 1Y Price Target: $40.80
• Price Target Upside: 47.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 75 Outperform
• Price Target: $31.00 ▲(12.16%Upside)

Kiniksa Pharmaceuticals scores well due to strong financial performance and positive earnings call, supported by robust technical indicators and strategic corporate events. However, the stock's valuation reflects high risk due to negative earnings, which tempers the overall score.

Positive Factors

Financial Health

Kiniksa Pharmaceuticals ended the year with $243.6 million of cash and equivalents and expects to be cash flow positive while funding clinical trials, indicating strong financial health.

Market Penetration

Approximately 13% of patients in Kiniksa's target recurrent pericarditis population are now actively on Arcalyst therapy, up from 9% penetration, showing significant market penetration growth.

Market Share

The increase to 28% from 17% in 1st recurrence patients indicates a positive trend for Arcalyst.

Negative Factors

Clinical Catalysts

The lack of clinical catalysts in 2025 means Arcalyst will be the main driver of the stock in the near term.

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

How the Company Makes Money

Kiniksa Pharmaceuticals makes money primarily through the development and commercialization of its proprietary drug products. The company generates revenue through sales of its approved therapies, licensing agreements, and strategic collaborations with other pharmaceutical companies. These partnerships may include co-development and co-commercialization agreements, which provide Kiniksa with milestone payments and royalties based on sales achievements. Additionally, the company may engage in research collaborations that offer funding to advance its clinical programs and further enhance its product pipeline.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Kiniksa Pharmaceuticals demonstrates strong revenue growth and improving profitability, with net loss significantly reduced. The balance sheet is stable with low debt levels, but past financial instability is a concern. Cash flow metrics are robust, suggesting efficient cash management.

Income Statement

Kiniksa Pharmaceuticals has shown impressive revenue growth, with significant increases over the past few years, including a 13.7% growth from 2024 to 2025 TTM. Gross profit margin is strong at approximately 93.8% in the TTM period. However, the company is still operating at a net loss, though it has improved significantly from previous years, reducing the net loss from $43.19 million in 2024 to $2.9 million in the TTM period. This indicates a positive trajectory towards profitability.

Balance Sheet

The balance sheet shows a healthy equity position with stockholders' equity growing to $457.49 million. The debt-to-equity ratio is low at approximately 0.02, indicating low leverage and reduced financial risk. However, the company's equity ratio of 76.3% highlights stability, but the historical negative equity in 2021 and prior years is a concern, pointing to past financial instability.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow growing by 72% from 2024 to the TTM period. The operating cash flow to net income ratio is exceptionally strong, indicating efficient cash management. Free cash flow to net income ratio also reflects a robust cash-generating ability. These metrics suggest strong operational efficiency and cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	423.24M	270.26M	220.18M	38.54M	0.00
Gross Profit	362.33M	213.74M	173.21M	29.44M	-3.81M
EBITDA	-45.62M	-22.86M	9.77M	-154.28M	-152.42M
Net Income	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Balance Sheet
Total Assets	580.55M	526.32M	459.67M	232.80M	349.46M
Cash, Cash Equivalents and Short-Term Investments	243.63M	206.37M	190.61M	182.20M	323.48M
Total Debt	9.86M	12.26M	5.92M	6.05M	6.99M
Total Liabilities	142.12M	87.48M	63.52M	47.76M	37.53M
Stockholders Equity	438.44M	438.84M	-492.03M	-675.40M	-517.47M
Cash Flow
Free Cash Flow	25.41M	13.17M	5.70M	-146.71M	-136.81M
Operating Cash Flow	25.69M	13.30M	5.81M	-126.30M	-136.53M
Investing Cash Flow	37.67M	-29.56M	-8.08M	128.63M	-23.44M
Financing Cash Flow	12.27M	1.50M	2.52M	5.88M	227.09M

Kiniksa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.64
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Neutral. The current price of 27.64 is below the 20-day moving average (MA) of 28.12, below the 50-day MA of 27.91, and above the 200-day MA of 23.37, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 43.14 is Neutral, neither overbought nor oversold. The STOCH value of 19.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KNSA.

Kiniksa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	80 Outperform	$2.11B	13.99	24.71%	―	20.62%	14.08%
KNSA	75 Outperform	$2.02B	―	-3.81%	―	59.45%	-290.38%
BEAM	56 Neutral	$2.17B	―	-38.04%	―	-82.38%	-164.76%
CGON	49 Neutral	$1.98B	―	-16.57%	―	―	―
Sector *	47 Neutral	C$200.31M	-3.37	-23.14%	1.85%	20.75%	-0.36%
IRON	43 Neutral	$2.10B	―	-23.34%	―	―	-14.19%
CNTA	33 Underperform	$2.10B	―	-74.29%	―	-100.00%	-25.86%

Kiniksa Pharmaceuticals Corporate Events

Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions

On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan

On April 17, 2025, Kiniksa Pharmaceuticals‘ Board of Directors approved a Long-Term Incentive Plan for its executive officers, aimed at achieving key milestones related to the development and FDA approval of KPL-387 for recurrent pericarditis. The plan includes cash awards, performance share units, and share options, with the potential for varying earnout percentages based on milestone achievement dates. This initiative reflects Kiniksa’s strategic focus on advancing KPL-387 and incentivizing its leadership to drive the company’s growth and market positioning.